“Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data from a late-stage trial presented at a major medical meeting on Monday.

The Phase 3 trial of 509 patients showed that Imdelltra extended median overall survival by more than five months to 13.6 months, compared with 8.3 months for standard-of-care chemotherapy, the company said…

Amgen said 27% of trial patients treated with Imdelltra experienced serious side effects, including low white blood cell counts, compared with 62% of chemotherapy patients.”

From Reuters.